A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Rewrite Therapeutics, a US-based DNA writing technologies spinout of University of California, Berkeley, has been acquired by genome editing company Intellia Therapeutics for $45m in an upfront payment and up to an additional $155m in milestone payments through a mix of stock and cash. Rewrite Therapeutics was founded in 2016. It raised $2m in a seed round led by Civilization Ventures and backed by Prefix Capital and Cystic Fibrosis Foundation in September 2021, according to deals database PitchBook.

StreetLight Data,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in